Matchpoint Therapeutics secured a $150 million Series B to advance an oral covalent small-molecule pipeline targeting autoimmune and inflammatory diseases. The financing expands resources for program development toward proof-of-concept while reinforcing investor focus on orally delivered immunomodulators. The round also reflects continued appetite for mechanistically distinct immune pathway interventions—especially those aiming for sustained suppression with manageable administration logistics compared with biologics and infusion regimens.